Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Sold by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. cut its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 19.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 335,840 shares of the company's stock after selling 82,800 shares during the period. Stratos Wealth Partners LTD. owned about 0.63% of Zevra Therapeutics worth $2,801,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ZVRA. FMR LLC raised its holdings in shares of Zevra Therapeutics by 282,687.5% in the third quarter. FMR LLC now owns 2,313,202 shares of the company's stock valued at $16,054,000 after buying an additional 2,312,384 shares during the last quarter. Stonepine Capital Management LLC purchased a new stake in shares of Zevra Therapeutics in the third quarter valued at about $4,858,000. Vestal Point Capital LP purchased a new stake in shares of Zevra Therapeutics in the third quarter valued at about $3,644,000. Propel Bio Management LLC purchased a new stake in shares of Zevra Therapeutics in the third quarter valued at about $1,248,000. Finally, Geode Capital Management LLC raised its holdings in shares of Zevra Therapeutics by 14.2% in the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company's stock valued at $7,246,000 after buying an additional 129,600 shares during the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Cantor Fitzgerald raised shares of Zevra Therapeutics to a "strong-buy" rating in a report on Wednesday, January 29th. Canaccord Genuity Group reduced their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, November 14th. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $21.57.

Zevra Therapeutics Price Performance

Shares of ZVRA traded up $0.01 during mid-day trading on Tuesday, reaching $7.54. 353,932 shares of the company's stock were exchanged, compared to its average volume of 405,453. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a 50-day simple moving average of $8.33 and a two-hundred day simple moving average of $8.02. Zevra Therapeutics, Inc. has a 52-week low of $4.20 and a 52-week high of $9.76. The company has a market cap of $402.49 million, a price-to-earnings ratio of -3.83 and a beta of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $3.70 million for the quarter, compared to analysts' expectations of $5.04 million. During the same period last year, the business earned ($0.40) earnings per share. On average, sell-side analysts predict that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.